OncBioMune CEO Dr. Jonathan Head to Present Abstract on Prostate Cancer Vaccine at Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

OncBioMune Pharmaceuticals (OTCMKTS:OBMP), a clinical stage biopharmaceutical company engaged in the development of novel cancer products and a proprietary vaccine technology, announces that OncBioMune Chief Executive Officer Dr. Jonathan Head will be making an abstract poster presentation today at the Second CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference: Translating Science into Survival. The conference is being hosted at the Sheraton New York Times Square Hotel in New York, New York from September 25-28.
Dr. Head is scheduled to make the presentation titled, “Phase 1 clinical trial of a PSA, IL-2, GM-CSF containing prostate cancer vaccine in PSA defined biochemical recurrent prostate cancer patients,” during the Reception and Poster Session A from 5:00-7:30 PM ET today at New York Hilton Midtown, Americas Halls I & II.
Connect with OncBioMune Pharmaceuticals (OTCMKTS:OBMP) to receive an Investor Presentation.